KIN-2787 is a potential treatment for BRAF class II or III alteration-positive and/or NRAS mutation-positive, metastatic or unresectable, stage IIB to IV malignant melanoma.
Publications
New Zealand approves melanoma reimbursement for Opdivo
New Zealand’s Pharmaceutical Management Agency, or PHARMAC, has given a reimbursement approval for Bristol-Myers Squibb’s ($BMY) Opdivo (nivolumab) to treat melanoma, while still in a back-and-forth with Merck ($MRK) on Keytruda (pembrolizumab) for the same indication.
Losing Nemo: Array pulls skin cancer NDA for binimetinib
Array BioPharma has yanked its NDA to the U.S. regulator for its late-stage melanoma candidate binimetinib after the agency told the biotech its phase 3 Nemo data wouldn’t cut it.
Immunocore wins FDA nod for first uveal melanoma treatment, also first T-cell receptor therapeutic
Uveal melanoma, an aggressive cancer of the eye, has been a particularly tough nut to crack for scientists trying to find a treatment.